反応 #44865
ord-47b27a62a832479db135ea1f68f94ace
反応方程式
4-{[4-({[(3-Isopropyl-2-oxo-2,3-dihydro′-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid
4-{[4-({[(3-Isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid
benzenesulfonic acid monohydrate
→
反応物
4-{[4-({[(3-Isopropyl-2-oxo-2,3-dihydro′-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid
4-{[4-({[(3-Isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid
benzenesulfonic acid monohydrate
試薬
なし
反応条件
詳細条件
See reaction.notes.procedure_details.
後処理
- 1濃縮it was concentrated
- 2その他The residue was dried
実験手順
To a suspension of 4-{[4-({[(3-Isopropyl-2-oxo-2,3-dihydro′-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid (750 mg, Step 13) in CH3CN (5 mL), a solution of benzenesulfonic acid monohydrate (288 mg) in CH3CN (5 mL) was added at room temperature. The resulting mixture was stirred at room temperature for 2 days and it was concentrated. The residue was dried to afford 909 mg (90%) of the titled compound as a solid.